Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acura Pharmaceuticals has received a $300,000 grant from the National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH) to fund Phase I development of its new, early stage Limitx abuse deterrent technology.
Subscribe to our email newsletter
Limitx is a new, early stage technology apart from the company’s other abuse deterrent technologies Aversion and Impede.
The NIDA grant is based on a proposal submitted by Acura to advance the development of a self-regulating hydromorphone tablet intended to deter abuse by excess oral consumption of the tablets.
Under the deal, Acura must complete Phase I development project by 28 February 2015, which is intended to optimize the formulation in preparation for clinical testing in Phase II.
The funding of Phase II development, for which an application has already been submitted, will be contingent upon evaluation by NIDA of the Phase I progress report and determination that the Phase I milestones were achieved, review and approval of other documents necessary for continuation, and availability of funds.
The company said that no assurance can be given that Phase II development funding will be provided by NIDA.
According to the proof of concept laboratory tests, Limitx showed the ability to limit the release of the active ingredient from tablets when multiple tablets are simultaneously introduced into simulated gastric fluid.